April 08, 2025
1 min watch
Save
VIDEO: Long-term data for lebrikizumab show possible management of itch
In this video, Raj Chovatiya, MD, PhD, discussed results of a study following patients with atopic dermatitis who were on lebrikizumab for 3 continuous years.
Chovatiya also discussed patient outcomes from ADAPT trial, which looked at patients who had previously been treated with dupilumab and the ADmirable trial, which looked at AD in people of color.